WHO WE ARE
At FlůID, we combined over 15 years experience in rational drug design and MRI brain imaging to create a unique proprietary molecular imaging method.
This novel method is capable of identifying small molecules localizing in the brain of small laboratory animals without the requirement of ionizing agents.
WHAT WE DO
By localizing clinical candidates after the initial scale-up synthesis and during the stability tests, value adding information for the clinical candidates is obtained increasing the chance of success for the traditional 14C or PET distribution studies.
Costs associated with traditional distribution studies are thus significantly reduced, and the risk in selecting the correct clinical candidate is mitigated.
Axel Mathieu | Ph.D.
President & CEO - FluoIDImg
Douglas Mental Health University Institute · Brain Imaging Center